Get the Stockscreener App
9.34
2.26%
-0.40
Nextcure Inc stock is traded at $9.34, with a volume of 6,928.
It is down -2.26% in the last 24 hours and down -7.80% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$9.74
Open:
$10.07
24h Volume:
6,928
Relative Volume:
0.15
Market Cap:
$32.87M
Revenue:
-
Net Income/Loss:
$-55.84M
P/E Ratio:
-0.5308
EPS:
-17.5951
Net Cash Flow:
$-49.61M
1W Performance:
-2.66%
1M Performance:
-7.80%
6M Performance:
-4.80%
1Y Performance:
+2,074%
1-Day Range:
$9.10
$10.07
1-Week Range:
$9.10
$11.14
52-Week Range:
$0.39
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
9.10 | 35.18M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
434.23 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.23 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
791.62 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.28 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
143.80 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure stock (US65343E1082): biotech shares react to recent strategic update and Nasdaq trading mo - AD HOC NEWS
SilverArc and Devesh Gandhi report 176,057 shares in NextCure (NXTC) - Stock Titan
TradingKey - TradingKey
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline - Investing.com
Lucid Capital Markets initiates coverage of NextCure (NXTC) with buy recommendation - MSN
NXTC (NextCure) earnings beat estimates by 67 percent, yet shares retreat despite EPS outperformance.Attention Driven Stocks - newser.com
How NextCure (NXTC) maintains its competitive edge | Q4 2025: Profit Exceeds ViewsUpside Surprise - newser.com
NextCure | 10-Q: Quarterly report - Moomoo
NextCure 1Q Loss/Shr $1.87 >NXTC - Moomoo
NextCure | 10-Q: Q1 2026 Earnings Report - Moomoo
NextCure (NASDAQ: NXTC) narrows loss but warns on going-concern and funding needs - Stock Titan
NextCure | 8-K: NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
FDA Fast Track and narrower loss mark Q1 2026 for NextCure (NASDAQ: NXTC) - Stock Titan
NextCure maps June cancer data, says cash lasts into 2027 - Stock Titan
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Weekly Voice
Simcere entities disclose 9.4% stake in NextCure (NXTC) - Stock Titan
NextCure initiates dose optimization study for ovarian cancer drug - Investing.com
NextCure initiates dose optimization study for ovarian cancer drug By Investing.com - Investing.com Nigeria
Biotechnology company NextCure Inc. announced it is accelerating the progress of its R&D projects by expanding its clinical research center network to Canada and Europe. - Bitget
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - The Manila Times
NextCure moves ovarian cancer drug into dose testing before ASCO - Stock Titan
NextCure Inc expected to post a loss of $1.81 a shareEarnings Preview - TradingView
What capacity utilization NextCure (NXTC)? (-2.47%) 2026-04-27Crowd Consensus Signals - Newser
NextCure (NXTC) Stock Rejected Order (Smart Money Exits) 2026-04-24Top Analyst Picks - Newser
NextCure (NASDAQ: NXTC) plans 2026 meeting, auditor, pay and equity plan votes - Stock Titan
NextCure to present SIM0505 cancer drug data at ASCO meeting - Investing.com
NextCure to present SIM0505 cancer drug data at ASCO meeting By Investing.com - Investing.com South Africa
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - The Manila Times
NextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026 - Quiver Quantitative
NextCure Inc stock (US65343E1082): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
Ladenburg Thalmann Upgrades NextCure (NXTC) - MSN
NXTC Forecast, Price Target & Analyst Ratings | NEXTCURE INC (NASDAQ:NXTC) - ChartMill
Resistance Check: Will Argan Inc benefit from rate cutsPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
GUOCHUN INTERNATIONAL INC. Reports No Revenue and Material Weaknesses in Q3 2025 10-Q/A Filing - Minichart
Published on: 2026-04-09 04:19:51 - baoquankhu1.vn
Surprises Report: Is NextCure Inc stock good for income investorsNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
FDA Gives Fast Track Status to SIM0505 in Platinum-Resistant Ovarian Cancer - CancerNetwork
Activity Recap: Is NextCure Inc a defensive stock2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Is NextCure (NXTC) Stock heavily shorted | Price at $12.10, Up 8.67%Popular Trader Picks - newser.com
Value Recap: How is NextCure Inc managing supply chain issues2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget
FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data - Stock Titan
Resistance Check: Is NextCure Inc exposed to currency risksMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Trend Report: Will Investcorp Credit Management BDC Inc Preferred Security outperform tech stocksWeekly Investment Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
NXTC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Sacral Fracture Risk After Short-Course RT for Rectal Cancer - Medscape
NXTC Stock Analysis: NextCure Inc. Biotech Gains 1.80 Percent to 10.72 Support Level - newser.com
Buyout Rumor: Will American Tower Corporation stock go up in YEAR2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
NXTC Should I Buy - Intellectia AI
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):